Related Experiment Video
Updated: May 31, 2026
06:28
Cerenkov Luminescence Imaging of Interscapular Brown Adipose Tissue
Published on: October 7, 2014
Multispectral Cerenkov luminescence tomography for small animal optical imaging
Antonello E Spinelli1, Chaincy Kuo, Brad W Rice
1Medical Physics Department, San Raffaele Scientific Institute, Via Olgettina N. 60, Milan, Italy. spinelli.antonello@hsr.it
Optics Express
|July 1, 2011
Summary
This study introduces multi spectral diffuse Cerenkov luminescence tomography (msCLT) for 3D in vivo imaging in mice. The novel method accurately reconstructs Cerenkov radiation bio-distribution, advancing preclinical imaging.
Area of Science:
- * Pre-clinical imaging
- * Optical imaging
- * Biomedical engineering
Background:
- * Cerenkov luminescence imaging (CLI) is a new technique for in vivo small animal imaging.
- * CLI detects Cerenkov radiation (CR) from beta particles in tissues.
- * Current methods lack detailed 3D bio-distribution information.
Purpose of the Study:
- * To present a novel image reconstruction method, multi spectral diffuse Cerenkov luminescence tomography (msCLT).
- * To enable 3D bio-distribution imaging of radiopharmaceuticals in vivo.
- * To assess the accuracy and resolution of the msCLT method.
Main Methods:
- * Developed and applied the msCLT method using multispectral 2D planar images.
- * Utilized narrow bandpass filters to capture wavelength-specific CR information.
- * Validated the method in vitro and in vivo using 32P-ATP in mice, with MRI for anatomical correlation.
Main Results:
- * msCLT successfully reconstructed 3D Cerenkov emission bio-distribution in vivo.
- * Spatial resolution of 1.5 mm FWHM at 6 mm depth was achieved.
- * Co-registered MRI confirmed accurate localization of CR in anatomical regions like the brain and heart.
Conclusions:
- * msCLT is a viable approach for in vivo 3D bio-distribution imaging of beta-minus emitting radiopharmaceuticals.
- * The technique offers improved spatial resolution and anatomical localization.
- * This advances preclinical research capabilities for targeted therapies and diagnostics.
